Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trialMohamed Hussein, Ahmad Deeb, Ziad A. Memish et al.|Trials|2020Cited by 132
Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi ArabiaHail M. Al-Abdely, Susan I. Gerber, Claire M. Midgley et al.|Emerging infectious diseases|2019Cited by 89
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory SyndromeYaseen M. Arabi, Adel Alothman, Ayed Y. Asiri et al.|New England Journal of Medicine|2020Cited by 80
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trialFaizah Alotaibi, Naif Khalaf Alharbi, Lindsey B. Rosen et al.|Influenza and Other Respiratory Viruses|2023Cited by 52
Heterogeneity of treatment effect of interferon-β1b and lopinavir–ritonavir in patients with Middle East respiratory syndrome by cytokine levelsYaseen M. Arabi, Naif Khalaf Alharbi, Ayed Y. Asiri et al.|Scientific Reports|2022Cited by 3